Home Actualité internationale CM – Pfizer reports positive results from the JADE DARE phase 3 study in atopic dermatitis
Actualité internationale

CM – Pfizer reports positive results from the JADE DARE phase 3 study in atopic dermatitis

Pfizer (PFE) announces that JADE DARE (B7451050), a 26-week Phase 3 study, has met its co-primary and key secondary efficacy endpoints.

Keywords:

Pfizer,Atopic dermatitis,Dupilumab,NYSE:PFE,Clinical trial,Pfizer, Atopic dermatitis, Dupilumab, NYSE:PFE, Clinical trial,,arrest,cardiovascular,childhood,children,chronic,covid-19,disease,immunology,Impact,inflammation,participants,Pfizer,rating,Safety,tablet,treatment,,

A LIRE AUSSI ...

Le nouveau téléprompteur d’Elgato est conçu pour les streamers.

Elgato, maker of the Stream Deck, just announced a teleprompter gadget. The...

Any huge fans of "Shrek" will have the opportunity to live like...

[quads id=1]